



WOMEN'S CANCER INITIATIVE
TATA MEMORIAL HOSPITAL

YEAR IN REVIEW IN GYNECOLOGICAL CANCERS

18th-19th DEC, 2021
SATURDAY & SUNDAY



Organised by : Gynecologic Oncology
Disease Management Group,
Tata Memorial Centre, Mumbai

Maharashtra Medical Council has awarded 3 CME points

Click on the link below for registration

<https://www.riveroute.in/wcigynyir2021>

Virtual Webinar Managed by

riveroute
Leaders in Streaming Modules



YEAR IN REVIEW IN GYNECOLOGICAL CANCERS

18th-19th DEC, 2021
SATURDAY & SUNDAY

Dear Friends and Colleagues,

Women's Cancer Initiative-Tata Memorial Hospital invites you for the **"Year In Review in Gynecological Cancers"**. This meeting will be held on a virtual platform on **18th and 19th December 2021**.

The pandemic has slowed down research, in spite of this many clinical, translational and basic science studies in the field of gynecological oncology were published this year. Data to be discussed at the YIR 2021 meeting has been chosen from major gynecological cancer meetings and noteworthy publications from peer reviewed journals, likely to make an impact on our daily clinical practice.

Please find below the registration link for the meeting. We request you to popularise this link amongst your colleagues.

<https://www.riverroute.in/wcigynyir2021>

We look forward to your participation in YIR 2021.

With best wishes



Dr. Amita Maheshwari
Organising Chairperson



Dr. Kedar Deodhar
Convener, Gynecologic Oncology
Disease Management Group



Dr. Biswajit Dash
Organising Secretary



Dr. Sushmita Rath
Organising Secretary

Click on the link below for registration

<https://www.riverroute.in/wcigynyir2021>

Virtual Webinar Managed by

riverroute
Leaders in Streaming Modules



YEAR IN REVIEW IN GYNECOLOGICAL CANCERS

18th-19th DEC, 2021
SATURDAY & SUNDAY

DAY 1

Dec, 18 2021, Saturday | 4.00 - 8.00 pm

Scientific Program

04.00 pm - 04.05 pm ● **Welcome Address**

Dr. Kedar Deodhar

04.05 pm - 04.10 pm ● **Overview of the Program**

Organising Chairperson: Dr. Amita Maheshwari

Session I: OVARIAN CANCER

Chairpersons:

Dr. Rama Joshi, Dr. Priya Tiwari

04.10 pm - 04.30 pm ● **PARP Inhibitors**

Speaker: Dr. Amit Agarwal

- Prevalence of BRCA1 and BRCA2 Mutations Among Patients With Ovarian, Primary Peritoneal, and Fallopian Tube Cancer in India: A Multicenter Cross-Sectional Study.
Gupta S. et al JCO Glob Oncol. 2021 Jun;7:849-861.
- Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial.
Banerjee S. et al Lancet Oncol. 2021 Dec;22(12):1721-1731.
- Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial.
Poveda A. et al Lancet Oncol. 2021 May;22(5):620-631.
- Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian cancer (HGOC).
Kwan T. et al Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021) 5537-5537

Click on the link below for registration

<https://www.riverroute.in/wcigynyir2021>

Virtual Webinar Managed by

riverroute

Leaders in Streaming Modules

Scientific Program

- v. Rucaparib vs. chemotherapy in patients with advanced, relapsed ovarian cancer and a deleterious BRCA mutation: Efficacy and safety from ARIEL4, a randomized phase 3 study.

Kristeleit R. et al, presented at: ESMO Gynaecological Cancers Virtual Congress; June 25-26, 2021.

- vi. Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial.

Mirza MR. et al Gynecol Oncol. 2020 Nov;159(2):442-448.

- vii. Fuzuloparib maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer: A multicenter, randomized, double-blind, placebo-controlled, phase III trial.

Li N. et al Society of Gynecologic Oncology (SGO) 2021 Annual Meeting on Women's Cancer. Abstract 11557.

Presented March 25, 2021.

- viii. PARP Inhibitor in Platinum-Resistant Ovarian Cancer: Single-Center Real-World Experience.

Agarwal A. et al JCO Glob Oncol. 2021 Apr;7:506-511.

- ix. Therapy-related myeloid neoplasms following treatment with PARP inhibitors: new molecular insights.

Martin JE. et al Ann Oncol. 2021 Aug;32(8):1046-1048.

- x. PARP inhibitors and newly second primary malignancies in cancer patients: a systematic review and safety meta-analysis of placebo randomized controlled trials.

Morice PM et al. Ann Oncol. 2021 Aug;32(8):1048-1050.

- xi. Maintenance olaparib rechallenge in patients with ovarian carcinoma previously treated with a PARP inhibitor: Phase IIIb OReO/ENGOT Ov-38 trial.

Pujade-Lauraine E et al Annals of Oncology (2021) 32 (suppl_5): S1283-S1346. 10.1016

04.30 pm - 04.35 pm ●

Primary debulking surgery versus NACT

Speaker: Dr. Sampada Desai

- i. Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer(SCORPION-NCT01461850)

Fagotti A. et al. Int J Gynecol Cancer 2020;30:1657-1664.

04.35 pm - 04.40 pm ●

HIPEC at secondary cytoreductive surgery

Speaker: Dr. Tanushree Jain

- i. Secondary Cytoreduction and Carboplatin Hyperthermic Intraperitoneal Chemotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: An MSK Team Ovary Phase II Study.

Zivanovic O et al. J Clin Oncol. 2021 Aug 10;39(23):2594-2604.

Scientific Program

04.40 pm - 05.20 pm • Panel Discussion: OVARIAN CANCER

Moderator: Dr. Senthil Rajappa

Panelists: Dr. Seema Gulia

Dr. Prasanth Ganesan

Dr. Sarika Gupta

Dr. Shahana Pervin

Dr. Vinotha Thomas

Dr. Neha Mittal

Dr. Sandeep Batra

05.20 pm - 05.30 pm • Concluding Remarks by Chairpersons

05.30 pm - 05.50 pm • Debate: Is there a role of secondary cytoreductive surgery in platinum sensitive relapsed ovarian cancer?

Moderator: Dr. Sudeep Gupta

Yes - Dr. S. P. Somashekhar

No - Dr. Neha Kumar

• Rebuttal - 2 mins (1 min each)

Concluding Remarks by Dr. Sudeep Gupta

05.50 pm - 06.05 pm

INAUGURATION

Address by Director TMC

Dr. Rajendra Badwe

Introduction to WCI

Dr. Sudeep Gupta

Address by

Mrs. Devieka Bhojwani

SESSION II: ENDOMETRIAL CANCER

Chairpersons:

Dr. Shalini Rajaram, Dr. K. Govind Babu,

Dr. S. K. Shrivastava

06.05 pm - 06.15 pm • ESGO/ESTRO/ESP and NCCN Guidelines – What is new?

Speaker: Dr. Rohini Kulkarni

06.15 pm - 06.20 pm • Minimally Invasive Surgery and Tumour Spill

Speaker: Dr. Shweta Rai

i. Intraoperative Tumor Spill during Minimally Invasive Hysterectomy for Endometrial Cancer:

A Survey Study.

Chang-Patel E. et al AAGL 2021; Virtual Poster 5497.

Scientific Program

06.20 pm - 06.25 pm ●

Sentinel Lymph Node Biopsy in Endometrial Cancer**Speaker: Dr. Richa Bansal**

- i. Assessment of Sentinel Lymph Node Biopsy vs Lymphadenectomy for Intermediate- and High-Grade Endometrial Cancer Staging.

Cusimano MC et al JAMA Surg. 2021 Feb 1;156(2):157-164

06.25 pm - 06.30 pm

Speaker: Dr. Rohit Ranade

- ii. Sentinel lymph node biopsy in high-grade endometrial cancer: a systematic review and meta-analysis of performance characteristics.

Marchocki Z et al Am J Obstet Gynecol. 2021 Oct; 225(4): 367.e1-367.e39.

06.30 pm - 06.35 pm ●

Adjuvant Therapy and Its Complications**Speaker: Dr. Karthiga Sivaprakasam**

- i. A Multi-Institutional Analysis of Adjuvant Chemotherapy and Radiation Sequence in Women with Stage IIIC Endometrial Cancer.

Hathout L et al Int J Radiat Oncol Biol Phys. 2021 Aug 1;110(5):1423-1431.

06.35 pm - 06.43 pm

Speaker: Dr. Santam Chakraborty

- ii. Long-Term Toxicity and Health-Related Quality of Life After Adjuvant Chemoradiation Therapy or Radiation Therapy Alone for High-Risk Endometrial Cancer in the Randomized PORTEC-3 Trial.

Post CCB et al Int J Radiat Oncol Biol Phys. 2021 Mar 15;109(4):975-986. doi: 10.1016/j.ijrobp.2020.10.030.

- iii. Radiation Therapy Techniques and Treatment-Related Toxicity in the PORTEC-3 Trial: Comparison of 3-Dimensional Conformal Radiation Therapy Versus Intensity-Modulated Radiation Therapy.

Wortman BG et al Int J Radiat Oncol Biol Phys. 2021 Oct 2;S0360-3016(21)02846-7

06.43 pm - 06.50 pm ●

Targeted Therapy**Speaker: Dr. Kripa Bajaj**

- i. A multicentre, open-label, randomized phase 3 study to compare the efficacy and safety of lenvatinib in combination with pembrolizumab vs. treatment of physician's choice in patients with advanced endometrial cancer: Study 309/KEYNOTE-775.

Makker V et al International Journal of Gynecologic Cancer 2021; 31:A4-A5.

- ii. Antitumor activity of dostarlimab in patients with mismatch repair-deficient/microsatellite instability-high tumors: A combined analysis of two cohorts in the GARNET study.

Dominique Berton et al Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021) 2564-2564a1

DAY 1

Dec, 18 2021, Saturday | 4.00 - 8.00 pm

Scientific Program

06.50 pm - 07.40 pm

● **Panel Discussion: ENDOMETRIAL CANCER**

Moderators: Dr. Jaya Ghosh

Dr. Yogesh Kulkarni

Panelists: Dr. Anupama Rajanbabu

Dr. Jannatul Ferdous

Dr. Veena P

Dr. Rupinder Sekhon

Dr. Chandrakant MV

Dr. Umesh Mahantshetty

Dr. Santosh Menon

Dr. Kripa Bajaj

07:40 pm - 07:50 pm

● **Concluding Remarks by Chairpersons**

Click on the link below for registration

<https://www.riverroute.in/wcigynyir2021>

Virtual Webinar Managed by

riverroute

* Leaders in Streaming Modules



YEAR IN REVIEW IN GYNECOLOGICAL CANCERS

18th-19th DEC, 2021
SATURDAY & SUNDAY

DAY 2

Dec, 19-2021, Sunday | 10.00 am - 1.30 pm

Scientific Program

SESSION III: CERVICAL CANCER

Chairpersons:

Dr. Swarupa Mitra, Dr. Neerja Bhatla,
Dr. Hemant Malhotra

10.00 am - 10.05 am

Conservative Surgery for low-risk early stage cervical cancer

Speaker: Dr. Biswajit Dash

- ConCerv: a prospective trial of conservative surgery for low-risk early-stage cervical cancer.

Schmeler KM. et al Int J Gynecol Cancer. 2021 Oct;31(10):1317-1325. doi: 10.1136/ijgc-2021-002921

10.05 am - 10.30 am
10.05 am - 10.10 am

Radiotherapy

Dr. Prachi Mittal

- Beyond Sedlis-A novel histology-specific nomogram for predicting cervical cancer recurrence risk: An NRG/GOG ancillary analysis.

Levinson K. et al Gynecol Oncol. 2021 Sep;162(3):532-538

10.10 am - 10.15 am

Dr. Abhishek Shinghal

- Late Toxicity After Adjuvant Conventional Radiation Versus Image-Guided Intensity-Modulated Radiotherapy for Cervical Cancer (PARCER): A Randomized Controlled Trial.

Chopra S J. Clin Oncol. 2021 Nov 20;39(33):3682-3692.

10.15 am - 10.20 am

Dr. Susovan Banerjee

- MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study.

Potter R. et al Lancet Oncol. 2021 Apr;22(4):538-547.

10.20 am - 10.25 am

Dr. Raviteja Miriyala

- Effectiveness of Sequential Chemoradiation vs Concurrent Chemoradiation or Radiation Alone in Adjuvant Treatment After Hysterectomy for Cervical Cancer: The STARS Phase 3 Randomized Clinical Trial.

Huang H. et al JAMA Oncol. 2021 Mar 1;7(3):361-369.

Click on the link below for registration

<https://www.riverroute.in/wcigynyir2021>

Virtual Webinar Managed by

riverroute

* Leaders in Streaming Modules

Scientific Program

10.25 am - 10.30 am

Dr. Lincoln Pujari

- v. Sequential Chemotherapy for Early-Stage, Post-Radical Hysterectomy Cervical Cancer: Are the STARS Aligned?

Randall LM. et al JAMA Oncol. 2021 Mar 1;7(3):353-354.

10.30 am - 10.45 am
10.30 am - 10.35 am

Targeted therapy in advanced cervical cancer
Speaker: Dr. Chakor Vora

- i. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study.

Coleman RL. et al Lancet Oncol. 2021 May;22(5):609-619.

10.35 am - 10.40 am

Speaker: Dr. Somnath Roy

- ii. Adjuvant chemotherapy following chemo radiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: The randomized phase III OUTBACK Trial (ANZGOG 0902, RTOG 1174, and NRG 0274)

Mileshkin LR. et al Journal of Clinical Oncology 2021 39:18_suppl, LBA3-LBA3.

10.40 am - 10.45 am

Speaker: Dr. Sushmita Rath

- iii. Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer.

Colombo N et al, N Engl J Med. 2021 Nov 11;385(20):1856-1867.

10.45 am - 10.50 am

Preventive oncology

Speaker: Dr. Pabashi Poddar

- i. Vaccine efficacy against persistent human papillomavirus (HPV) 16/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre, prospective, cohort study

Basu P et al ,Lancet Oncol. 2021 Nov;22(11):1518-1529.

10.50 am - 11.40 am

Panel Discussion: CERVICAL CANCER

**Moderators: Dr. Bhavana Rai,
Dr. Sachin Khurana**

**Panelists: Dr. Vivek Agarwala
Dr. Lavanya G.
Dr. Tapas Dora
Dr. AFM Kamal Uddin
Dr. Satinder Kaur
Dr. Monisha Gupta
Dr. Bharat Rekhi
Dr. Sharmila Pimple
Dr. Joydeep Ghosh**

11.40 am - 11.50 am

Concluding Remarks by Chairpersons

Scientific Program

SESSION IV: RAPID-FIRE

Chairpersons:

Dr. S.K. Giri, Dr. Seema Singhal

11.50 am - 12.00 pm

What is new in Gynec Oncopathology- An Overview of WHO Blue book 2020

Speaker: Dr. Kedar Deodhar

12.00 pm - 12.20 pm

Ovarian Cancer

Speaker: Dr. Sudeep Gupta

i. Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial.

Morgan RD. et al *Lancet Oncol.* 2021 Feb;22(2):277-288.

ii. Cisplatin and paclitaxel is associated with improved progression-free survival compared to cisplatin alone during interval debulking surgery with HIPEC in women with advanced epithelial ovarian cancer

Chambers LM. et al *SGO 2021; Abstract 101.*

iii. Efficacy and Safety of First-line Single-Agent Carboplatin vs Carboplatin Plus Paclitaxel for Vulnerable Older Adult Women With Ovarian Cancer: A GINECO/GCIG Randomized Clinical Trial.

Falandry C. et al, *JAMA Oncol.* 2021 Jun 1;7(6):853-861.

iv. Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39).

Moore KN et al, *J Clin Oncol.* 2021 Jun 10;39(17):1842-1855.

v. Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study.

Pujade-Lauraine E. et al, *Lancet Oncol.* 2021 Jul;22(7):1034-1046

vi. Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA).

Hamanishi J. et al, *J Clin Oncol.* 2021 Nov 20;39(33):3671-3681

vii. Risk of breast cancer in women treated with ovarian stimulation drugs for infertility: a systematic review and meta-analysis.

Beebejaun Y et al, *Fertil Steril.* 2021 Jul;116(1):198-207

viii. Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study.

Schrijver LH. et al, *Am J Obstet Gynecol.* 2021 Jul;225(1):51.e1-51.e17.

Scientific Program

12.20 pm - 12.35 pm

ix. Association of Germline BRCA Pathogenic Variants With Diminished Ovarian Reserve: A Meta-Analysis of Individual Patient-Level Data.

Turan V. et al, J Clin Oncol. 2021 Jun 20;39(18):2016-2024.

x. Image-Guided Percutaneous Thermal Ablation of Oligometastatic Ovarian and Non-Ovarian Gynecologic Tumors. J Vasc Interv Radiol

Yuan F et al ,2021 May;32(5):729-738.

Cervical Cancer

Speaker: Dr. Supriya Chopra

i. Genetic variation in cervical preinvasive and invasive disease: a genome-wide association study.

Bowden SJ. et al,Lancet Oncol. 2021 Apr;22(4):548-557.

ii. Machine learning applications in radiation oncology.

Field M et al Phys Imaging Radiat Oncol. 2021 Jun 24;19:13-24.

iii. Development and clinical validation of Knowledge-based planning for Volumetric Modulated Arc Therapy of cervical cancer including pelvic and para aortic fields.

Swamidas J et al,Phys Imaging Radiat Oncol. 2021 May 26;18:61-67.

iv. Single Application Multifractionated Image Guided Adaptive High-Dose-Rate Brachytherapy for Cervical Cancer: Dosimetric and Clinical Outcomes.

Mahantshetty U et al, Int J Radiat Oncol Biol Phys. 2021 Nov 1;111(3):826-834.

v. A large, multicenter, retrospective study on efficacy and safety of stereotactic body radiotherapy in oligometastatic cervical cancer (MITO-RT2/RAD)

Macchia G. et al International Journal of Gynecologic Cancer 2021;31:A52-A53.

vi. Management of oligo-metastatic and oligo-recurrent cervical cancer: A pattern of care survey within the EMBRACE research network.

Chopra S et al, Radiother Oncol. 2021 Feb;155:151-159..

vii. Stereotactic body radiation therapy for oligometastatic gynecologic malignancies: A systematic review.

Yegya-Raman N, Gynecol Oncol. 2020 Nov;159(2):573-580

viii. Effect of COVID-19 Pandemic on Gynecological Cancer Radiation During Complete Nationwide Lockdown: Observations and Reflections From Tertiary Care Institute in India.

Shinghal A et al Adv Radiat Oncol. 2021 Nov-Dec;6(6):100725.

ix. Prophylactic Extended-Field Irradiation in Patients With Cervical Cancer: A Literature Review.

Wang W. et al ,Front Oncol. 2020 Oct 2;10:579410.

x. Uterine perforation during brachytherapy for cervical cancer: Complications, outcomes, and best practices for forward treatment planning and management.

Small W Jr et al,Brachytherapy. 2021 May-Jun;20(3):557-564.

Scientific Program

12.35 pm - 12.45 pm

● Endometrial Cancer

Speaker: Dr. Shweta Tahlan

- i. Prospective Cohort Study of Pre- and Post-Diagnosis Obesity and Endometrial Cancer Survival.
Kokts-Porietis RL et al ,J Natl Cancer Inst. 2021 Oct 1:djab197.
- ii. Complete pathological response following levonorgestrel intrauterine device in clinically stage 1 endometrial adenocarcinoma: Results of a randomized clinical trial.
Janda M et al. Gynecol Oncol. 2021 Apr;161(1):143-151.
- iii. Prospective phase II trial of levonorgestrel intrauterine device: nonsurgical approach for complex atypical hyperplasia and early-stage endometrial cancer.
Westin SN. et al, Am J Obstet Gynecol. 2021 Feb;224(2):191.e1-191.e15.
- iv. Evaluation of treatment effects in patients with endometrial cancer and POLE mutations: An individual patient data meta-analysis.
McAlpine JN. et al, Cancer. 2021 Jul 15;127(14):2409-2422.
- v. Phase II Study of the WEE1 Inhibitor Adavosertib in Recurrent Uterine Serous Carcinoma.
Liu JF et al,J Clin Oncol. 2021 May 10;39(14):1531-1539.
- vi. Association Between Adjuvant Therapy and Survival in Stage II-III Endometrial Cancer: Influence of Malignant Peritoneal Cytology.
Matsuo K et al Ann Surg Oncol. 2021 Nov;28(12):7591-7603

12.45 pm - 12.55 pm

● Miscellaneous (GTN/Vulvar Cancer)

Speaker: Dr. Bhagyalaxmi Nayak

- i. Predictors for single-agent resistance in FIGO score 5 or 6 gestational trophoblastic neoplasia: a multicentre, retrospective, cohort study.
Braga A. et al , Lancet Oncol. 2021 Aug;22(8):1188-1198.
- ii. FIGO staging for carcinoma of the vulva: 2021 revision.
Olawaiye AB et al, Int J Gynaecol Obstet. 2021 Oct;155(1):43-47.
- iii. Radiotherapy Versus Inguinofemoral Lymphadenectomy as Treatment for Vulvar Cancer Patients With Micrometastases in the Sentinel Node: Results of GROINSS-V II.
Oonk MHM. et al, J Clin Oncol. 2021 Nov 10;39(32):3623-3632.
- iv. Pembrolizumab for Vulvar Squamous Cell Carcinoma: Results From the Phase 2 KEYNOTE-158 Study.Frommer RS, et al Abstract presented at: Society of Gynecological Oncology 2021 Virtual Annual Meeting on Women's Cancer; March 19-21, 2021; Virtual. Abstract 11603.

12.55 pm - 01.05 pm

● Q & A

01.05 pm - 01.10 pm

● Vote of Thanks

Dr. Biswajit Dash

Dr. Sushmita Rath

Organising Secretaries